BostonGene-Integrated Genomic Registry (BIGR)

Status Recruiting

Clinical Trial Summary

The purpose of this project is to develop a comprehensive database of genomic, transcriptomic, molecular, and clinical characteristics of oncology patients to discover, define, and develop genomic and transcriptomic markers to improve future clinical outcomes across cancer types

Clinical Trial Description

Immuno- and targeted therapies have shown promising results for many types of cancer (1). However, the effectiveness of these treatments is not optimal for many patients (2). Therefore, further research is needed to discover, define, and develop genomic, transcriptomic, and integrated molecular markers that can improve clinical outcomes across cancer types (3). Unfortunately, current research is restricted by the limited availability of genomic and transcriptomic results linked to clinical outcomes (3). This study will allow for the collection of key clinical data, including longitudinal follow-up, linked with individual genetic and molecular findings in a single comprehensive registry-based databank. Analysis of these data may lead to advances across cancer subtypes through the identification of transcriptomic and genomic associations with therapies. Clinical and pathological information, including detailed genetic information from a participant's tumor biopsy, will be obtained by the research staff for each participant enrolled in the BIGR Study. Clinical information will include relevant details about the patient's diagnosis and treatment and will be stored in a secure electronic registry database. No extra scans or procedures for this study will be collected as part of this study. Information will be collected regarding a participant's initial diagnosis, treatment, and outcome. To obtain this information, study staff will contact participants or a participant's doctor at regular time intervals for up to 15 years. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04991922
Study type	Observational
Source	BostonGene
Contact	Nathan Fowler
Phone	+1-617-658-4545
Email	nathan.fowler@bostongene.com
Status	Recruiting
Phase
Start date	July 1, 2021
Completion date	July 1, 2036

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05640115` - Obstruction of Malignancy: Percutaneous Renal vs Endoscopic Stent	Early Phase 1
Recruiting	`NCT02891642` - Liquid Biopsy With Immunomagnetic Beads Capture Technique for Malignant Cell Detection in Body Fluid
Completed	`NCT02282449` - Power Injectable Versus a Non-Power Injectable, Upper Arm, TIVAD for Chemotherapy	N/A
Completed	`NCT01199822` - Study of the Safety and Pharmacokinetics of IMC-3G3 in Japanese Patients With Solid Tumors	Phase 1
Completed	`NCT01212731` - Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
Recruiting	`NCT04122469` - The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease	N/A
Recruiting	`NCT03561727` - Risk Factors for Development of Incisional Hernia in Transverse Incisions	N/A
Terminated	`NCT03251924` - A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT03997968` - A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT00092222` - Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity	Phase 2
Recruiting	`NCT05770102` - DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition	Phase 2/Phase 3
Recruiting	`NCT05886764` - Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials	N/A
Not yet recruiting	`NCT05992363` - Tandem Polyurethane Stents Compared to Single Silicone Stent for Malignant Ureteral Obstruction	Phase 3
Recruiting	`NCT05761366` - Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor	Phase 2
Recruiting	`NCT04887545` - Immune- and Microenvironment- Proteogenomics Profiling for Classifying Lung Cancer Patients
Completed	`NCT03061955` - Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)
Completed	`NCT03909464` - Non-Invasive Neurosensory Testing For Chemotherapy-Induced Peripheral Neuropathy
Active, not recruiting	`NCT02649491` - Using an Electronic Nose to Predict Gastrointestinal Consequences of Pelvic Radiotherapy	N/A
Recruiting	`NCT02776995` - Tumor Monitoring Using Thermography During Radiation Therapy	N/A
Active, not recruiting	`NCT01242072` - Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies	Phase 1